JP2012528887A5 - - Google Patents

Download PDF

Info

Publication number
JP2012528887A5
JP2012528887A5 JP2012514171A JP2012514171A JP2012528887A5 JP 2012528887 A5 JP2012528887 A5 JP 2012528887A5 JP 2012514171 A JP2012514171 A JP 2012514171A JP 2012514171 A JP2012514171 A JP 2012514171A JP 2012528887 A5 JP2012528887 A5 JP 2012528887A5
Authority
JP
Japan
Prior art keywords
amino acid
pharmaceutical composition
joint
subject
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012514171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528887A (ja
JP5906183B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/037390 external-priority patent/WO2010141811A2/en
Publication of JP2012528887A publication Critical patent/JP2012528887A/ja
Publication of JP2012528887A5 publication Critical patent/JP2012528887A5/ja
Application granted granted Critical
Publication of JP5906183B2 publication Critical patent/JP5906183B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012514171A 2009-06-04 2010-06-04 骨障害を治療するための、および、体重を管理するための化合物および方法 Expired - Fee Related JP5906183B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18420909P 2009-06-04 2009-06-04
US61/184,209 2009-06-04
PCT/US2010/037390 WO2010141811A2 (en) 2009-06-04 2010-06-04 Compounds and methods for treating bone disorders and controlling weight

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015253422A Division JP2016106098A (ja) 2009-06-04 2015-12-25 骨障害を治療するための、および、体重を管理するための化合物および方法

Publications (3)

Publication Number Publication Date
JP2012528887A JP2012528887A (ja) 2012-11-15
JP2012528887A5 true JP2012528887A5 (cg-RX-API-DMAC10.html) 2013-07-25
JP5906183B2 JP5906183B2 (ja) 2016-04-20

Family

ID=43298544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012514171A Expired - Fee Related JP5906183B2 (ja) 2009-06-04 2010-06-04 骨障害を治療するための、および、体重を管理するための化合物および方法
JP2015253422A Pending JP2016106098A (ja) 2009-06-04 2015-12-25 骨障害を治療するための、および、体重を管理するための化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015253422A Pending JP2016106098A (ja) 2009-06-04 2015-12-25 骨障害を治療するための、および、体重を管理するための化合物および方法

Country Status (5)

Country Link
US (1) US9220746B2 (cg-RX-API-DMAC10.html)
EP (1) EP2437768B1 (cg-RX-API-DMAC10.html)
JP (2) JP5906183B2 (cg-RX-API-DMAC10.html)
ES (1) ES2602629T3 (cg-RX-API-DMAC10.html)
WO (1) WO2010141811A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183212A1 (en) * 2009-01-08 2010-07-22 Numira Biosciences, Inc. Methods and compositions for imaging cartilage and bone
EP2437768B1 (en) * 2009-06-04 2016-08-10 The University of North Carolina At Chapel Hill Compounds and methods for treating bone disorders and controlling weight
EP2970387A4 (en) * 2013-03-12 2016-07-27 Univ North Carolina COMPOUNDS AND METHOD FOR THE TREATMENT OF ADIPOSITAS AND WEIGHT CONTROL
BR112019016250A2 (pt) * 2017-02-06 2020-04-14 Alize Pharma Iii Sas peptídeos isolados, uso do peptídeo isolado, método para prevenção ou tratamento de um distúrbio ósseo, método para melhorar a formação óssea, método para inibir a reabsorção óssea, método para induzir a deposição óssea, método para induzir a maturação óssea, método de expandir células tronco ex vivo e composição farmacêutica
CA3100665A1 (en) 2018-05-24 2019-11-28 Amolyt Pharma Heparin-binding domain of igfbp-2 in the treatment of metabolic disorders
WO2021011283A1 (en) * 2019-07-12 2021-01-21 Northwestern University Insulin like growth factor binding protein bioactive peptide fragments
CN114634552B (zh) * 2022-04-14 2022-12-13 中国农业大学 一种抗肥胖十三肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
AU746423B2 (en) * 1997-05-05 2002-05-02 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7504374B2 (en) 2000-10-24 2009-03-17 Warsaw Orthopedic, Inc. Method for inducing deposition and maturation of bone comprising a co-therapeutic regimen of LMP-1 and BMP-2
EP1646648A2 (en) * 2003-07-15 2006-04-19 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
WO2006034832A2 (en) 2004-09-27 2006-04-06 Univ Muenchen L Maximilians Use of igfbp-2 in senescence diseases and for the maintenance of organ functions
US20080286287A1 (en) 2005-03-30 2008-11-20 Murdoch Childrens Research Institute Methods and Agents for Modulating Cellular Activity
EP2462946B1 (en) * 2006-08-16 2014-07-09 National Research Council of Canada Method of inhibiting cathepsin activity
WO2009019254A1 (en) * 2007-08-03 2009-02-12 Pharis Biotec Gmbh Igfbp-2 c-terminal fragments and uses thereof
EP3085707B1 (en) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr binding peptides and their uses
EP2437768B1 (en) * 2009-06-04 2016-08-10 The University of North Carolina At Chapel Hill Compounds and methods for treating bone disorders and controlling weight

Similar Documents

Publication Publication Date Title
US11576980B2 (en) Compositions and methods of treating muscle atrophy and myotonic dystrophy
TWI578995B (zh) 利尿鈉肽受體npr-b促效劑之用途
KR102410986B1 (ko) Fgf-18 화합물 투여 처방
JP2019505486A5 (cg-RX-API-DMAC10.html)
CA2929637C (en) USE OF IL-22 DIMERS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF PANCREATITIS
UA98462C2 (ru) Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
RS52710B (sr) Lečenje poremećaja hrskavice sa fgf-18
RU2012148716A (ru) Способы и композиции для улучшения оссеоинтеграции имплантата
KR101493437B1 (ko) 컨센서스 펩티드
WO2022085791A1 (ja) 老化により機能低下した骨格筋の筋機能改善剤
JP2014522414A5 (cg-RX-API-DMAC10.html)
WO2015110082A1 (zh) 牙源性干细胞和基因修饰的牙源性干细胞的用途
JP2019522046A5 (cg-RX-API-DMAC10.html)
AU2018214650B2 (en) Compounds, compositions and uses thereof for improvement of bone disorders
JP2010189399A (ja) 生理活性ペプチド及びこれを含有する薬剤
JP4931306B2 (ja) 骨形成を安全に促進させる医薬複合剤
JP5300943B2 (ja) 骨形成を安全に促進させる医薬複合剤
JP6906760B2 (ja) 持効性/徐放性骨破壊阻止剤
KR101388235B1 (ko) 메클리진을 포함하는 관절염 예방 및 치료용 조성물
JP5454805B2 (ja) 骨形成を安全に促進させる医薬複合剤
JP5629940B2 (ja) 関節疾患治療用の組み合わせ製剤
WO2008126974A1 (en) Composition for preventing and treating osseous metabolic disease
EP3315146A1 (en) Bone bioactive composition and uses thereof
Fröhlich Analogies in the Adverse Immune Effects of Wear Particles, Environmental Particles, and Medicinal Nanoparticles
HK1242607A1 (en) Agent for preventing onset of idiopathic osteonecrosis of femoral head and/or suppressing progress of same